Comparative Pharmacology
Head-to-head clinical analysis: NAPROSYN versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROSYN versus TOLECTIN 600.
NAPROSYN vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category C
Category C
NSAID
NSAID